Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib

Gossamer Bio, Inc.

Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.
Pro forma cash, cash equivalents and marketable securities $396M as of March 31, 2024.
PROSERA Phase 3 PAH study topline results expected Q4 2025; registrational Phase 3 PH-ILD to start mid-2025.
Net loss $41.9M ($0.19 per share) for Q1 2024 vs $49.2M ($0.52 per share) in Q1 2023.
R&D expenses $32.4M in Q1 2024 down from $37.8M YoY, primarily due to terminated programs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Gossamer Bio, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share, EPS $0.19 per share.

Period: the quarter ended March 31, 2024
Net income: Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share
EPS: $0.19 per share
Result: reported results

Exact text from the filing

On May 7, 2024, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-24-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.